Her2/neu Il ruolo del Pertuzumab - Università degli Studi di Torino
Her2/neu Il ruolo del Pertuzumab - Università degli Studi di Torino
Her2/neu Il ruolo del Pertuzumab - Università degli Studi di Torino
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Stu<strong>di</strong></strong> clinici<br />
www.roche-trials.com<br />
www.clinicaltrials.gov<br />
• Agus DB et al, Phase I clinical study of pertuzumab, a novel HER<br />
<strong>di</strong>merization inhibitor, in patients with advanced cancer, J Clin Oncol,<br />
23:2534, 2005<br />
• Gordon MS et al, Clinical activity of pertuzumab (rhuMAb 2C4), a HER<br />
<strong>di</strong>merization inhibitor, in advanced ovarian cancer: potential pre<strong>di</strong>ctive<br />
relationship with tumor HER2 activation status, J Clin Oncol, 24:4324-<br />
32, 2006<br />
• Open label, phase II, multicenter study of efficacy and safety for two<br />
<strong>di</strong>fferent doses of a recombinant humanized antibody to <strong>Her2</strong> (rhuMAb<br />
2C4) administered every 3 weeks to patient with metastatic breast<br />
cancer with low expression of <strong>Her2</strong> – (http://roche-trials.com/patient/trialresults/stur117.html)
Change language